Condition: Healthy · Systemic Lupus Erythematosus · Rheumatoid Arthritis · Sponsor: Eli Lilly and Company
The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Nucleus Network | Brisbane, Australia | Recruiting |
| Nucleus Network | Melbourne, Australia | Recruiting |
| Peking University First Hospital | Beijing, China | Not Yet Recruiting |
| Peking University Third Hospital | Beijing, China | Not Yet Recruiting |
| Xiangya Hospital of Central South University | Changsha, China | Not Yet Recruiting |
| Anhui Provincial Hospital | Hefei, China | Not Yet Recruiting |
| Renji Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, China | Not Yet Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, China | Not Yet Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07276958